Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesTrends in RA patients' adherence to subcutaneous anti-TNF therapies and costs
Current Medical Research and Opinion, 06/24/09
Borah BJ et al. – Study reports that etanercept (ETA) users had longer treatment duration, were more likely to adhere to their medication regimen and had lower rheumatoid arthritis (RA)-related pharmacy and RA-related total costs compared with adalimumab (ADA) users.
Methods- Main objectives of study were:
- To examine adherence to ADA and ETA and health care costs in RA pts, and
- To explore the association between adherence, utilization and costs
- RA pts treated with etanercept or adalimumab during Jan 2005-Dec 2005 were identified
- Patient adherence and costs were assessed during the 1 yr post-index period (first dispensing date)
- Nonadherence was modeled using logistic regression
- Hazard ratios (HR) comparing time to discontinuation were estimated using Cox proportional hazard (PH) models
- Compared with ADA users, ETA users had longer average treatment duration
- Unadjusted adherence rates for naïve and existing users were 63% and 70% (ADA), and 65% and 73% (ETA)
- Compared with ETA users, ADA users were more likely to be nonadherent
- Existing ADA users were more likely to discontinue their medication than existing ETA users
- Compared with ADA users, ETA users had lower RA-related pharmacy costs and RA-related total costs
Today in Other Drugs...keeping you current
Receive free subspecialty "5-minute updates" via email
Doxycycline for osteoarthritis of the knee or hip
Cochrane Reviews, 10/23/09
Safety and efficacy of testosterone gel in the treatment of male hypogonadism
Clinical Interventions in Aging, 10/12/09
Biphasic effects of hormone treatment on risk of cardiovascular disease
Sexuality, Reproduction & Menopause, 10/20/09
Today in Pharmacoeconomics...keeping you current
Receive free subspecialty "5-minute updates" via email
Treatment of Very Early Rheumatoid Arthritis With Symptomatic Therapy, Disease-Modifying Antirheumatic Drugs, or Biologic Agents. A Cost-Effectiveness Analysis
Annals of Internal Medicine, 11/03/09
Use and cost of branded and generic drugs in patients with coronary heart disease-results from a prospective survey of 1008 patients in two London hospitals
QJM: An International Journal of Medicine, 10/16/09
Clinical and Economic Comparison of Frovatriptan Versus other Oral Triptans in the Treatment of Acute Migraine in the Real-World Setting
Clinical Drug Investigation, 10/15/09
Sponsor
Article Search
Sponsor